XML 37 R12.htm IDEA: XBRL DOCUMENT v3.25.3
Commitments
 9 Months Ended
Sep. 30, 2025
Commitments [Abstract]  
COMMITMENTS

NOTE 6 – COMMITMENTS 

 

In April 2025, the Company wholly owned subsidiary, INmune Bio International Ltd., entered into an agreement whereby the Company leases manufacturing space from a third party in the United Kingdom for 2 years. The lease requires payments of approximately $76,000 each quarter during the first year and $152,000 each quarter during the second year. The lease commencement date is August 2025.

 

As of September 30, 2025, the maturities of our lease liabilities are as follows:

 

(in thousands, except years)    
2025  $68 
2026   729 
2027   405 
Total lease payments   1,202 
Less: imputed interest   (122)
Present value of future lease payments   1,080 
Less: operating lease, current liabilities   (457)
Long-term operating lease liabilities  $623 
      
Weighted-average remaining lease term   1.7 years 
      
Weighted-average discount rate   12.0%

 

During the three and nine months ended September 30, 2025 the Company recognized $134,000 and $229,000, respectively, of lease expense.

 

During the three and nine months ended September 30, 2024, the Company recognized $40,000 and $120,000, respectively, of lease expense.

 

During April 2025, the Company’s wholly-owned subsidiary, INmune Bio International. Ltd., entered into a 2-year collaboration agreement with a vendor whereby it makes fixed payments to the vendor in exchange for services pursuant to manufacturing CORDStrom in the United Kingdom. A summary of the commitments payable for these services pursuant to the agreement is as follows as of September 30, 2025:

 

(in thousands, except years)    
2026  $1,449 
2027   1,177 
Total  $2,626